Alliqua BioMedical plans to expand its portfolio of regenerative technologies by acquiring the business of wound care product maker, Soluble Systems.

Following the acquisition, a new subsidiary will be formed that will be publicly traded and renamed as Alliqua BioMedical, where Soluble Systems’ assets will be transferred.

The consideration for the acquisition includes payments of $35 million, including an issue of approximately 17.6 million of the acquirer company’s shares valued at $0.89 a share and amounting to approximately $15.7 million in value, an assumption of $12.4 million of senior debt, repayment worth $5.4 million of subordinated debt due, $1 million in cash, and $0.5 million of other consideration.

"Integumen plans to acquire Innovenn UK from Venn Life Sciences and Helium Rising Stars Fund for a purchase consideration of $6.11 million."

In addition, the acquirer company will issue warrants to the target company to buy four million shares of the new subsidiary at a price of $1.07 per share.

Cowen and Company is acting as financial advisor for Alliqua BioMedical for the transaction.

Integumen plans to acquire Innovenn UK from Venn Life Sciences and Helium Rising Stars Fund for a purchase consideration of $6.11 million.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The acquisition will enable Integumen to further broaden its skin science, oral health and wound care businesses and allows Venn Life Sciences to strengthen its drug development and clinical research services.